238 related articles for article (PubMed ID: 30016275)
1. BCL2L12 improves risk stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia.
Avgeris M; Stamati L; Kontos CK; Piatopoulou D; Marmarinos A; Xagorari M; Baka M; Doganis D; Anastasiou T; Kosmidis H; Gourgiotis D; Scorilas A
Clin Chem Lab Med; 2018 Nov; 56(12):2104-2118. PubMed ID: 30016275
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse.
Stamati L; Avgeris M; Kosmidis H; Baka M; Anastasiou T; Piatopoulou D; Scorilas A; Gourgiotis D
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2023-36. PubMed ID: 25982455
[TBL] [Abstract][Full Text] [Related]
4. miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment.
Piatopoulou D; Avgeris M; Marmarinos A; Xagorari M; Baka M; Doganis D; Kossiva L; Scorilas A; Gourgiotis D
Br J Cancer; 2017 Sep; 117(6):801-812. PubMed ID: 28787435
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
6. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease-based risk stratification in Chinese childhood acute lymphoblastic leukemia by flow cytometry and plasma DNA quantitative polymerase chain reaction.
Cheng SH; Lau KM; Li CK; Chan NP; Ip RK; Cheng CK; Lee V; Shing MM; Leung AW; Ha SY; Cheuk DK; Lee AC; Li CH; Luk CW; Ling SC; Hrusak O; Mejstrikova E; Leung Y; Ng MH
PLoS One; 2013; 8(7):e69467. PubMed ID: 23936021
[TBL] [Abstract][Full Text] [Related]
8. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
[TBL] [Abstract][Full Text] [Related]
9. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
[TBL] [Abstract][Full Text] [Related]
10. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
11. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
Attarbaschi A; Mann G; Dworzak M; Urban C; Fink FM; Dieckmann K; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Feb; 114(4):148-57. PubMed ID: 12060981
[TBL] [Abstract][Full Text] [Related]
12. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.
Conter V; Bartram CR; Valsecchi MG; Schrauder A; Panzer-Grümayer R; Möricke A; Aricò M; Zimmermann M; Mann G; De Rossi G; Stanulla M; Locatelli F; Basso G; Niggli F; Barisone E; Henze G; Ludwig WD; Haas OA; Cazzaniga G; Koehler R; Silvestri D; Bradtke J; Parasole R; Beier R; van Dongen JJ; Biondi A; Schrappe M
Blood; 2010 Apr; 115(16):3206-14. PubMed ID: 20154213
[TBL] [Abstract][Full Text] [Related]
13. Impact of minimal residual disease on relapse in childhood acute lymphoblastic leukemia: Lessons learnt from a tertiary cancer center in India.
Mishra V; Jain S; Anand V; Malhotra P; Tejwani N; Kapoor G
Pediatr Hematol Oncol; 2023; 40(6):517-528. PubMed ID: 36930957
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004.
Kamps WA; van der Pal-de Bruin KM; Veerman AJ; Fiocco M; Bierings M; Pieters R
Leukemia; 2010 Feb; 24(2):309-19. PubMed ID: 20016528
[TBL] [Abstract][Full Text] [Related]
15. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
[TBL] [Abstract][Full Text] [Related]
16. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
[TBL] [Abstract][Full Text] [Related]
17. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
[TBL] [Abstract][Full Text] [Related]
19. Increased BCL2L12 expression predicts the short-term relapse of patients with TaT1 bladder cancer following transurethral resection of bladder tumors.
Foutadakis S; Avgeris M; Tokas T; Stravodimos K; Scorilas A
Urol Oncol; 2014 Jan; 32(1):39.e29-36. PubMed ID: 23790536
[TBL] [Abstract][Full Text] [Related]
20. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]